Long-Term Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis

被引：0
|
作者：
Rubin, David T. [1 ]
Cree, Bruce A. C. [2 ]
Wolf, Douglas C. [3 ]
Alekseeva, Olga [4 ]
Charles, Lorna [5 ]
Petersen, AnnKatrin [5 ]
Sheffield, James K. [5 ]
Cheng, Chun-Yen [5 ]
Riolo, Jon V. [5 ]
Silva, Diego [5 ]
Lublin, Fred D. [6 ]
Cohen, Jeffrey A. [7 ]
Danese, Silvio [8 ]
机构：
[1] Univ Chicago Med, Ctr Inflammatory Bowel Dis, Chicago, IL USA
[2] Univ Calif San Francisco, Weill Inst Neurosci, San Francisco, CA USA
[3] Atlanta Gastroenterol Associates, Ctr Crohns Dis & Ulcerat Colitis, Atlanta, GA USA
[4] Nizhny Novgorod Reg Clin Hosp, Nizhnii Novgorod, Nizhegorod, Russia
[5] Bristol Myers Squibb, Princeton, NJ USA
[6] Mt Sinai Med Ctr, New York, NY USA
[7] Cleveland Clin, Mellen Ctr MS Treatment & Res, Cleveland, OH USA
[8] Univ Vita Salute San Raffaele, IRCCS San Raffaele Sci Inst, Milan, Lombardia, Italy
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2023年 / 118卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S911
引用
收藏
页码：S680 / S680
页数：1
相关论文
共 50 条
  • [41] Long-Term Endoscopic and Histological Outcomes of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis With up to 3 Years of Treatment
    Sands, Bruce E.
    Kobayashi, Taku
    Wu, Jianmin
    Wang, Isabella Yali
    Zhu, Baojin
    Redondo, Isabel
    Peyrin-Biroulet, Laurent
    Walsh, Alissa
    Magro, Fernando
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1042 - S1043
  • [42] INCIDENCE OF INFECTIONS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH OZANIMOD AND RELATIONSHIP TO SIGNIFICANT LYMPHOPENIA: RESULTS FROM A POOLED SAFETY ANALYSIS
    Rieder, Florian
    Wolf, Douglas C.
    Charles, Lorna
    Kollengode, Kanthi
    Hsu, Kate
    Patel, Aditya
    Ghosh, Subrata
    GASTROENTEROLOGY, 2021, 160 (06) : S339 - S340
  • [43] CLINICAL REMISSION DEMONSTRATED WITH ORAL OZANIMOD IN THE OVERALL POPULATION AND ACROSS MULTIPLE SUBGROUPS OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE TOUCHSTONE TRIAL
    Feagan, Brian G.
    Sandborn, William J.
    D'Haens, Geert R.
    Hanauer, Stephen B.
    Wolf, Douglas C.
    Vermeire, Severine
    Ghosh, Subrata
    Petersen, AnnKatrin
    Hua, Steven
    Shan, Kevin
    Liu, Jerry
    GASTROENTEROLOGY, 2019, 156 (06) : S1103 - S1104
  • [44] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: results from the DAYBREAK open-label extension study
    Steinman, L.
    Comi, G.
    Bar-Or, A.
    Selmaj, K. W.
    Arnold, D. L.
    Hartung, H. -P.
    Montalban, X.
    Havrdova, E. K.
    Sheffield, J. K.
    Minton, N.
    Janjua, A.
    Huang, V.
    Silva, D.
    Kappos, L.
    Cohen, J. A.
    Cree, B. A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 548 - 549
  • [45] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: interim analysis of the DAYBREAK open-label extension study
    Selmaj, K. W.
    Steinman, L.
    Comi, G.
    Bar-Or, A.
    Arnold, D. L.
    Hartung, H. -P.
    Montalban, X.
    Havrdova, E. K.
    Krakovich, A.
    Sheffield, J. K.
    Cheng, C. -Y.
    Minton, N.
    Silva, D.
    Kappos, L.
    Cohen, J. A.
    Cree, B. A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 359 - 360
  • [46] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: interim analysis of the DAYBREAK open-label extension study
    Selmaj, K. W.
    Steinman, L.
    Comi, G.
    Bar-Or, A.
    Arnold, D. L.
    Hartung, H. -P.
    Montalban, X.
    Havrdova, K.
    Hoogerheyde, J.
    Afsari, S.
    Sheffield, J. K.
    Shi, F.
    Minton, N.
    Silva, D.
    Kappos, L.
    Cohen, J. A.
    Cree, B. A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 617 - 618
  • [47] Clinical remission demonstrated with oral ozanimod in the overall population and across multiple subgroups of patients with moderately to severely active ulcerative colitis in the TOUCHSTONE trial
    Feagan, B. G.
    Sandborn, W. J.
    D'Haens, G.
    Hanauer, S.
    Wolf, D. C.
    Vermeire, S.
    Ghosh, S.
    Petersen, A.
    Hua, S. Y.
    Shan, K.
    Liu, J.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S464 - S464
  • [48] Matching-adjusted indirect comparisons of efficacy outcomes between etrasimod and ozanimod for moderately to severely active ulcerative colitis
    Jairath, Vipul
    Raine, Tim
    Leahy, Thomas P.
    Potluri, Ravi
    Wosik, Karolina
    Gruben, David
    Cappelleri, Joseph C.
    Hur, Peter
    Bartolome, Lauren
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2025, 14 (04)
  • [49] One Fell Swoop: Ozanimod for Ulcerative Colitis and Multiple Sclerosis
    Figueroa, Gabriela
    Forster, Erin
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 : S12 - S12
  • [50] THE EFFECT OF OZANIMOD ON CIRCULATING NEUTROPHILS: RESULTS FROM THE TRUE NORTH STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Harris, Sarah
    Wu, Chun
    Li, Yicong
    Maddux, Rachel
    Hu, Sarah
    Petersen, AnnKatrin
    GASTROENTEROLOGY, 2022, 162 (07) : S973 - S973
12345